Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic Apixaban and Levels of Anti-factor Xa activitY (GALAXY) Study
TCTR20250606001Phase 1Recruiting
- Sponsor
- Atlanta Medicare
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of apixaban in venous thromboembolism (VTE) and Atrial fibrillation (AFib), sponsored by Atlanta Medicare. Primary endpoint: Anti-factor Xa activity. Started Jul 2025; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on TCTR20250606001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250606001.